Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Optic Disc Classification by Deep Learning versus Expert Neuro-Ophthalmologists

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A New Glycogen Storage Disease Caused by a Dominant PYGM Mutation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Neuroinflammatory markers associate with cognitive decline after major surgery: findings of an explorative study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. One year of Football Fitness improves L1-L4 BMD, postural balance and muscle strength in women treated for breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Effect of K ATP Channel Blocker Glibenclamide on CGRP-Induced Headache and Hemodynamic in Healthy Volunteers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The Association of Low Vitamin K Status with Mortality in a Cohort of 138 Hospitalized Patients with COVID-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: Migraine is a prevalent and disabling neurological disease. Its genesis is poorly understood, and there remains unmet clinical need. We aimed to identify mechanisms and thus novel therapeutic targets for migraine using human models of migraine and translational models in animals, with emphasis on amylin, a close relative of calcitonin gene-related peptide (CGRP).

METHODS: Thirty-six migraine without aura patients were enrolled in a randomized, double-blind, 2-way, crossover, positive-controlled clinical trial study to receive infusion of an amylin analogue pramlintide or human αCGRP on 2 different experimental days. Furthermore, translational studies in cells and mouse models, and rat, mouse and human tissue samples were conducted.

RESULTS: Thirty patients (88%) developed headache after pramlintide infusion, compared to 33 (97%) after CGRP (p = 0.375). Fourteen patients (41%) developed migraine-like attacks after pramlintide infusion, compared to 19 patients (56%) after CGRP (p = 0.180). The pramlintide-induced migraine-like attacks had similar clinical characteristics to those induced by CGRP. There were differences between treatments in vascular parameters. Human receptor pharmacology studies showed that an amylin receptor likely mediates these pramlintide-provoked effects, rather than the canonical CGRP receptor. Supporting this, preclinical experiments investigating symptoms associated with migraine showed that amylin treatment, like CGRP, caused cutaneous hypersensitivity and light aversion in mice.

INTERPRETATION: Our findings propose amylin receptor agonism as a novel contributor to migraine pathogenesis. Greater therapeutic gains could therefore be made for migraine patients through dual amylin and CGRP receptor antagonism, rather than selectively targeting the canonical CGRP receptor. ANN NEUROL 2021.

OriginalsprogEngelsk
TidsskriftAnnals of Neurology
Vol/bind89
Udgave nummer6
Sider (fra-til)1157-1171
ISSN0364-5134
DOI
StatusUdgivet - jun. 2021

ID: 65608616